May. 12 at 2:23 PM
$NRXS
NRXS: NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth:
https://ir.neuraxis.com/neuraxis-reports-record-first-quarter-2026-financial-results-driven-by-80-year-over-year-revenue-growth/
1Q26 Financial Highlights:
Revenues increased 80% year over year to
$1.6M, reflecting the AMA Category I CPT® code assignment for Percutaneous Electrical Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payor coverage.
Expanded gross margin by 200 basis points and improved operating loss by 24% year over year as more IB-Stim® devices were sold at full price due to the recently secured Category I CPT® Code.
Cash balance was
$7.1 million as of March 31, 2026. Subsequently, the Company successfully completed an additional
$2.1 million through its at-the-market equity offering and warrant exercises in April and May of 2026
